[go: up one dir, main page]

WO2016193997A3 - Process for the preparation of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and pharmaceutically acceptable salts thereof - Google Patents

Process for the preparation of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and pharmaceutically acceptable salts thereof Download PDF

Info

Publication number
WO2016193997A3
WO2016193997A3 PCT/IN2016/000142 IN2016000142W WO2016193997A3 WO 2016193997 A3 WO2016193997 A3 WO 2016193997A3 IN 2016000142 W IN2016000142 W IN 2016000142W WO 2016193997 A3 WO2016193997 A3 WO 2016193997A3
Authority
WO
WIPO (PCT)
Prior art keywords
methylbutan
dihydroquinoline
fluorobenzyl
oxo
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2016/000142
Other languages
French (fr)
Other versions
WO2016193997A2 (en
Inventor
Srinivasan Thirumalai Rajan
Sajja Eswaraiah
Ghojala Venkat Reddy
Mallepally VENKAT REDDY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MSN Laboratories Pvt Ltd
Original Assignee
MSN Laboratories Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MSN Laboratories Pvt Ltd filed Critical MSN Laboratories Pvt Ltd
Publication of WO2016193997A2 publication Critical patent/WO2016193997A2/en
Publication of WO2016193997A3 publication Critical patent/WO2016193997A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C07D215/32—Esters
    • C07D215/34—Carbamates

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a process for the preparation of 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid represented by the following structural formula-1 and pharmaceutically acceptable salts thereof.
PCT/IN2016/000142 2015-06-03 2016-06-03 Process for the preparation of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and pharmaceutically acceptable salts thereof Ceased WO2016193997A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2784CH2015 2015-06-03
IN2784/CHE/2015 2015-06-03

Publications (2)

Publication Number Publication Date
WO2016193997A2 WO2016193997A2 (en) 2016-12-08
WO2016193997A3 true WO2016193997A3 (en) 2017-01-19

Family

ID=57441012

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2016/000142 Ceased WO2016193997A2 (en) 2015-06-03 2016-06-03 Process for the preparation of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and pharmaceutically acceptable salts thereof

Country Status (1)

Country Link
WO (1) WO2016193997A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114213450A (en) * 2021-12-29 2022-03-22 南京杰运医药科技有限公司 Synthesis method of methoxymethyl dimethoxysilane

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004046115A1 (en) * 2002-11-20 2004-06-03 Japan Tobacco Inc. 4-oxoquinoline compounds and utilization thereof as hiv integrase inhibitors
WO2011004389A2 (en) * 2009-06-18 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of elvitegravir
WO2014056464A1 (en) * 2012-10-12 2014-04-17 Zentiva, K.S. A new production method and new intermediates of synthesis of elvitegravir

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004046115A1 (en) * 2002-11-20 2004-06-03 Japan Tobacco Inc. 4-oxoquinoline compounds and utilization thereof as hiv integrase inhibitors
WO2011004389A2 (en) * 2009-06-18 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of elvitegravir
WO2014056464A1 (en) * 2012-10-12 2014-04-17 Zentiva, K.S. A new production method and new intermediates of synthesis of elvitegravir

Also Published As

Publication number Publication date
WO2016193997A2 (en) 2016-12-08

Similar Documents

Publication Publication Date Title
WO2015110897A3 (en) Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
CA2826751C (en) Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
WO2016079751A3 (en) A process for preparation of vortioxetine and polymorphs thereof
MX2018001491A (en) Methods for preparation of bile acids and derivatives thereof.
WO2016159577A3 (en) 1,2-naphthoquinone derivative and method for preparing same
WO2015187774A8 (en) 3,6-dichlorosalicylic acid compounds and related synthetic processes
WO2016071435A3 (en) Synthesis of copanlisib and its dihydrochloride salt
WO2014192030A3 (en) An improved process for preparation of dabigatran etexilate and pharmaceutically acceptable acid addition salts thereof
WO2016125191A3 (en) Processes for the preparation of vortioxetine hydrobromide
WO2014125506A3 (en) A process for the preparation of ivacaftor and its intermediates
WO2014207567A3 (en) Process for the preparation of abiraterone and intermediates thereof
WO2015068175A3 (en) An improved process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof
WO2016166720A3 (en) Polymorphs of afatinib and its salts and process for the preparation of quinazolinyl derivatives
WO2016077832A3 (en) PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS
WO2015121877A3 (en) Polymorphs of lomitapide and its salts
WO2015128875A3 (en) A process for preparation of dabigatran etexilate mesylate and intermediates thereof
WO2015052568A3 (en) Solid forms of curcumin and derivatives thereof
WO2015181802A3 (en) Oral pharmaceutical composition of isotretinoin
WO2016195377A3 (en) Composition of pranlukast-containing solid preparation with improved bioavailability and method for preparing same
WO2017055932A3 (en) Improved propionibacterium strains for the production of propionic acid
WO2017098533A3 (en) Process for preparation of lisdexamphetamine
WO2016193997A3 (en) Process for the preparation of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and pharmaceutically acceptable salts thereof
WO2017093866A3 (en) An improved process for the preparation of indigo carmine
WO2015087343A3 (en) An improved process for the preparation of nilotinib and pharmaceutically acceptable salts thereof
WO2016075703A3 (en) An improved process for preparation of 5-amino-2,4-di-tert- butylphenol or an acid addition salt thereof

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16802705

Country of ref document: EP

Kind code of ref document: A2